Fig. 1 · Structure

Documents & Downloads

XAV 939

Cat. No. A10994 CAS 284028-89-3

Tankyrase inhibitor (Wnt/β-catenin)

XAV 939 is a TNKS inhibitor (IC50 values are 0.011 and 0.004 μM for TNKS1 and TNKS2 respectively).

In Stock

Publications for XAV 939

3 publications citing this product

  1. Esteban Zamudio-Martínez, .et al. , Cell Commun Signal, 2025, Nov 5;23:477 PMID: 41194181
  2. Shizu Aikawa, .et al. , EMBO J, 2017, Jul 14; 36(14): 2146-2160 PMID: 28588064
  3. Mikaël M. Martino, .et al. , Nat Commun, 2016, 7: 11051 PMID: 27001940

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

XAV 939 inhibits tankyrase-mediated ADP-ribosylation. A comparative enzyme study also found potent inhibition of full-length PARP1 and PARP2, so its effects should not be interpreted as tankyrase-selective solely from compound treatment. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
TNKS2 (Cell-free assay) 4 nM
TNKS1 (Cell-free assay) 11 nM

Cellular Effect

Cell Line Activity Value Description Reference
A549 IC50 12.3 μM Growth inhibition of human A549 cells after 72 hrs by MTT assay [PMID: 29934219]
COLO 320DM GI50 17 μM Antiproliferative activity against human COLO320DM cells assessed as inhibition of cell growth measured after 4 days by CellTiter-Glo assay [PMID: 30883102]
DLD-1 IC50 0.707 μM Inhibition of tankyrase in human DLD1 cells assessed as reduction in Wnt activity after 24 hrs by TCF-luciferase reporter gene assay [PMID: 25299683]
HEK293 IC50 0.078 μM Inhibition of mouse Wnt3A signaling in human HEK293 cells after 1 day by super top flash luciferase reporter gene assay [PMID: 22260203]
HEK293 IC50 0.078 μM Inhibition of Wnt signaling in human HEK293 cells assessed as inhibition of forskolin-induced cAMP response element activation by STF luciferase reporter gene assay [PMID: 23879431]
HEK293 IC50 0.078 μM Inhibition of WNT3A signaling in HEK293 cells by luciferase reporter gene assay in presence of forskolin [PMID: 23844574]
HEK293 IC50 272 μM Inhibition of Tankyrase in human HEK293 cells assessed as inhibition of Wnt pathway by Wnt3a-induced STF assay [PMID: 23316926]
HEK-293T IC50 51 nM Inhibition of beta-casein-dependent canonical Wnt3 pathway in human HEK293T cells by luciferase reporter gene assay [PMID: 22191557]
Sf21 IC50 0.0053 μM Inhibition of N-terminal GST-tagged TNKS2 (unknown origin) expressed in baculovirus infected sf21 cells after 60 mins by LC-MS analysis [PMID: 23879431]
Sf21 IC50 17 nM Inhibition of N-terminal GST-tagged human TNKS-2 (849 to 1166 residues) expressed in in insect sf21 cells preincubated for 2 hrs followed by substrate addition measured after 30 mins [PMID: 27163581]
Sf9 IC50 2.1 nM Inhibition of human N-terminal GST-tagged TNKS2 (667 to 1166 residues) expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay [PMID: 31042381]
Sf9 IC50 4.2 nM Inhibition of human N-terminal GST-tagged TNKS1 (1001 to 1327 residues) expressed in baculovirus infected Sf9 insect cells using histone as substrate measured after 1 hr by horseradish peroxidase-coupled chemiluminescence assay [PMID: 31042381]
SW480 GI50 > 50 μM Growth inhibition of human SW480 cells by Cell-titer-fluor reagent based assay [PMID: 31769984]
SW480 EC50 0.371 μM Stabilization of Axin2 in human SW480 cells after 24 hrs by sandwich ELISA [PMID: 22260203]

14 records · Scroll to view more

In Vitro Studies

In breast cancer cell models, XAV939 increased Axin protein and inhibited Wnt3a-driven transcriptional responses. In MDA-MB-231 cells, Wnt reporter inhibition persisted across the tested serum concentrations. [2]

XAV939 inhibited MDA-MB-231 growth in low serum (72-h growth IC50, 1.5 μM). Growth inhibition was absent under optimal serum in MDA-MB-231, DLD-1 and SW480 cells, illustrating that pathway inhibition does not guarantee growth suppression. [2]

Enzyme inhibition and PARP-family selectivity

Biochemical assay · Recombinant human TNKS1 SAM–ART, TNKS2 ART, and full-length PARP1/PARP2 [1]

XAV939 inhibited both tankyrases and full-length PARP1/2. The construct-dependent comparison limits claims of tankyrase selectivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
TNKS1 SAM–ART inhibitionIC50 94.6 nM[1]
TNKS2 ART inhibitionIC50 5.2 nM[1]
Full-length PARP1 inhibitionIC50 74.1 nM[1]
Full-length PARP2 inhibitionIC50 26.9 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response series; IC50 is an assay endpoint.
Exposure duration
15 min preincubation before NAD+ addition.
Method
ADP-ribosylation assay; NAD+ at or below each construct’s KM.
Vehicle
1% DMSO; same-batch DMSO controls.
Reported limits
Individual XAV939 concentration series and enzyme-specific reaction durations not transcribed; SI not retrieved.
Methods and source locations

Compound reported in the paper: XAV 939; Compound label in the paper: XAV939

Evidence concerns the material tested by the authors; it does not establish performance or purity of a current Adooq lot.

Table 3, XAV939 column (PDF p. G); Figure 4B (p. F); In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics (p. G)

TNKS1 SAM–ART inhibition: Table 3 reported fit; not a cellular treatment dose. — Table 3, XAV939 column (PDF p. G); Figure 4B (p. F); In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics (p. G)

TNKS2 ART inhibition: Table 3 reported fit. — Table 3, XAV939 column (PDF p. G); Figure 4B (p. F); In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics (p. G)

Full-length PARP1 inhibition: Table 3 reported fit. — Table 3, XAV939 column (PDF p. G); Figure 4B (p. F); In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics (p. G)

Full-length PARP2 inhibition: Table 3 reported fit. — Table 3, XAV939 column (PDF p. G); Figure 4B (p. F); In Vitro ADP-Ribosylation Assay and Data Analysis and Statistics (p. G)

Axin stabilization and Wnt-response inhibition

Cell-based study · Human MDA-MB-231 breast cancer cells; MCF-7 and murine EMT6 provide protein-response context. [2]

XAV939 increased Axin protein and suppressed Wnt3a-driven transcriptional responses. In MDA-MB-231 cells, reporter inhibition persisted across the tested serum conditions.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Axin protein responseQualitative immunoblot Axin1 increased in MDA-MB-231, MCF-7 and EMT6 cells; Axin2 increased in MDA-MB-231 cells.[2]
Wnt3a-induced TOPFLASH activity in MDA-MB-231 cellsQualitative reporter response Inhibited at 0.2%, 1.25% and 5% FBS.[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM for protein/target-gene experiments; 1 or 5 μM in the serum-comparison reporter experiment.
Exposure duration
Overnight; Figure 1 also tests Wnt3a for the last 4 h.
Method
Immunoblot; normalized TOPFLASH/Renilla reporter and RT-PCR.
Vehicle
DMSO control.
Co-treatment
Wnt3a-conditioned medium; control conditioned medium comparators.
Reported limits
No isolated-ligand dose or exact overnight duration specified in these captions.
Methods and source locations

Compound reported in the paper: XAV 939; Compound label in the paper: XAV939

Evidence concerns the material tested by the authors; it does not establish performance or purity of a current Adooq lot.

Figures 1A–C and 2C–D; Results: XAV939 increases Axin levels / inhibition of Wnt signaling; Methods: Compounds, Transfections and Reporter assays

Axin protein response: Actin loading control; Wnt3a-present/absent comparisons. — Figure 1A–C and caption

Wnt3a-induced TOPFLASH activity in MDA-MB-231 cells: Firefly normalized to Renilla; means ± SD of three replicates. No exact inhibition percentage inferred. — Figure 2C and caption

Serum-dependent growth inhibition

Cell-based study · MDA-MB-231 breast cancer cells; DLD-1 and SW480 colorectal cancer cells under optimal serum. [2]

Growth inhibition in low-serum MDA-MB-231 cells did not persist under optimal serum. This limits generalization from Wnt-response inhibition to antiproliferative activity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
MDA-MB-231 growth in 1.25% FBSGrowth IC50 1.5 μM[2]
Growth at 5% FBS (MDA-MB-231) or 10% FBS (DLD-1, SW480)Qualitative negative result No growth inhibition by XAV939 under the tested conditions; XAV939 IC50 shown as NA.[2]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response series plotted in Figures 5B and 6; no single treatment dose.
Exposure duration
72 h
Method
Sulforhodamine B growth assay.
Vehicle
DMSO-normalized growth.
Co-treatment
XAV939 tested alone; 21H7 is a separate comparator, not a combination.
Reported limits
Full per-point concentrations not transcribed from logarithmic curves.
Methods and source locations

Compound reported in the paper: XAV 939; Compound label in the paper: XAV939

Evidence concerns the material tested by the authors; it does not establish performance or purity of a current Adooq lot.

Figures 5B and 6A–C and captions; Methods: Cell proliferation and colony growth assays; Results: XAV939 inhibits the growth of MDA-MB-231 breast cancer cells

MDA-MB-231 growth in 1.25% FBS: SRB at 72 h; explicitly printed IC50. — Figure 5B inset and caption

Growth at 5% FBS (MDA-MB-231) or 10% FBS (DLD-1, SW480): SRB at 72 h; means ± SD from three independent experiments performed in triplicate. 21H7 inhibited growth in the same assays. — Figure 6A–C and caption

In Vivo Studies

In a mouse calvarial-defect model, local XAV-939 co-delivery with MSCs (authors’ Il1r1/Myd88−/− designation) in fibrin reduced four-week bone regeneration relative to saline co-delivery. This result concerns an MSC-assisted repair setting. [3]

In male ICR mice with surgically induced osteoarthritis, repeated intra-articular hydrogel delivery of XAV939 reduced cartilage destruction in the treated joint. [4]

Local XAV-939 reduced MSC-assisted bone repair

Animal study · Wild-type C57BL/6-background mouse calvarial defects; surgery at 10–12 weeks; MSCs designated Il1r1/Myd88−/− by authors. [3]

XAV-939 co-delivery reduced MSC-associated bone regeneration at four weeks relative to saline co-delivery.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Calvarial defect coverageDirection and significance Reduced versus saline; P<0.001; n=6 per condition; means ± s.e.m.[3]

Conditions shared by the study groups

Route
Local delivery into calvarial defect within fibrin matrix.
Frequency
Co-delivery at defect treatment.
Treatment course
Bone regeneration assessed 4 weeks later.
Vehicle
Fibrin matrix; saline comparator.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
MSC + XAV-939 fibrin co-delivery
1 mM final XAV-939 concentration in 40 μl fibrin matrix per defect.
Same designated MSCs in fibrin matrix with saline; MK-2206 is a separate comparator arm.Lower defect coverage than the saline co-delivery group (P<0.001); means ± s.e.m., n=6 per condition.[3]
MSC + XAV-939 fibrin co-delivery
Model: Mouse calvarial defects receiving MSCs designated Il1r1/Myd88−/− in Figure 6; donor genotype grouping is retained as reported.
Reported limits: Figure 6 does not distinguish separate versus pooled Il1r1- and Myd88-deficient donor cells. Sex and whether n denotes mice or defects are not specified for this panel.
Methods and source locations

Compound reported in the paper: XAV 939; Compound label in the paper: XAV-939

Evidence concerns the material tested by the authors; it does not establish performance or purity of a current Adooq lot.

Figure 6g–h and caption; Results: IL-1β impairs the Akt/GSK-3β/β-catenin pathway in MSCs; Methods: Animals, Calvarial defect model, Microcomputed tomography

Calvarial defect coverage: MicroCT at 4 weeks; ANOVA with Bonferroni pairwise comparisons. No bar-height percentage estimated. — Figure 6g–h and caption

MSC + XAV-939 fibrin co-delivery · Figure 6g–h and caption; Results: IL-1β impairs the Akt/GSK-3β/β-catenin pathway in MSCs; Methods: Animals, Calvarial defect model, Microcomputed tomography

Local XAV939 preserved cartilage in experimental osteoarthritis

Animal study · Eight-week-old male ICR mice; destabilization of the medial meniscus (DMM). [4]

Hydrogel-delivered XAV939 attenuated cartilage destruction in this local delivery model.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cartilage destructionOARSI grade, qualitative direction Lower with XAV939 versus DMM vehicle; n=13 versus n=14; means ± s.e.m.[4]

Conditions shared by the study groups

Route
Intra-articular.
Frequency
Days 10, 20, 30, 40 and 50 after surgery, as shown in Figure 6e.
Treatment course
Endpoint day 56 after surgery.
Vehicle
Ascorbyl-palmitate hydrogel, prepared with DMSO and water, suspended in PBS.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
DMM + hydrogel XAV939
10 nmol drug in 10 μl PBS-suspended hydrogel (PBS:hydrogel=1:1) per administration.
DMM + vehicle hydrogel; sham + vehicle also shown. IWR-1 is a separate comparator.Lower OARSI cartilage-destruction grade with XAV939; XAV939 n=13, DMM vehicle n=14. Matrix and SOX9 staining were retained.[4]
DMM + hydrogel XAV939
Model: Eight-week-old male ICR mice with DMM-induced osteoarthritis.
Reported limits: No systemic exposure or clinical efficacy established; exact OARSI group means not tabulated in the read locations.
Methods and source locations

Compound reported in the paper: XAV 939; Compound label in the paper: XAV939

Evidence concerns the material tested by the authors; it does not establish performance or purity of a current Adooq lot.

Figure 6e–i and caption; Methods: Chemical Inhibitors, Preparation and in vivo evaluation of hydrogels, Experimental OA in mice, Histology and immunohistochemistry, Statistics

Cartilage destruction: Safranin O histology graded by three blinded observers. Caption specifies Kruskal–Wallis; general methods also specify Mann–Whitney post-testing. No exact grade inferred. — Figure 6e–g; Histology and immunohistochemistry; Statistics

DMM + hydrogel XAV939 · Figure 6e–i and caption; Methods: Chemical Inhibitors, Preparation and in vivo evaluation of hydrogels, Experimental OA in mice, Histology and immunohistochemistry, Statistics

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 284028-89-3
Applications Tankyrase inhibitor (Wnt/β-catenin)
Formula C14H11F3N2OS
Molecular Weight 312.3
SMILES
C1CSCC2=C1NC(=NC2=O)C3=CC=C(C=C3)C(F)(F)F

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 12 mg/mL (38.42 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
1 mg/mL
Vehicle
4% DMSO+corn oil

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Thorsell AG, Ekblad T, Karlberg T, et al. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors. Journal of medicinal chemistry (2017). PMID: 28001384 DOI: 10.1021/acs.jmedchem.6b00990 Source material
  2. [2] Bao R, Christova T, Song S, et al. Inhibition of tankyrases induces Axin stabilization and blocks Wnt signalling in breast cancer cells. PloS one (2012). PMID: 23144924 DOI: 10.1371/journal.pone.0048670 Source material
  3. [3] Martino MM, Maruyama K, Kuhn GA, et al. Inhibition of IL-1R1/MyD88 signalling promotes mesenchymal stem cell-driven tissue regeneration. Nature communications (2016). PMID: 27001940 DOI: 10.1038/ncomms11051 Source material
  4. [4] Kim S, Han S, Kim Y, et al. Tankyrase inhibition preserves osteoarthritic cartilage by coordinating cartilage matrix anabolism via effects on SOX9 PARylation. Nature communications (2019). PMID: 31653858 DOI: 10.1038/s41467-019-12910-2 Source material

Publications

3 publications citing this product

  1. Esteban Zamudio-Martínez, .et al. , Cell Commun Signal, 2025, Nov 5;23:477 PMID: 41194181
  2. Shizu Aikawa, .et al. , EMBO J, 2017, Jul 14; 36(14): 2146-2160 PMID: 28588064
  3. Mikaël M. Martino, .et al. , Nat Commun, 2016, 7: 11051 PMID: 27001940
Press to skip carousel

You May Also Consider

A-966492

A10019 CAS 934162-61-5

A-966492 displayed high potency against the poly(ADP-ribose) polymerase-1 (PARP-1) enzyme with a K(i) of 1 nM and an EC(50) of 1 nM in a whole cell assay.
The price depends on the options chosen on the product page

Starting at $20.00

View Sizes
Veliparib

A10026 CAS 912444-00-9

ABT-888(Veliparib) is a potential anti-cancer drug acting as a PARP inhibitor.
The price depends on the options chosen on the product page

Starting at $25.00

View Sizes
Rucaparib (AG-014699) phosphate

A10045 CAS 459868-92-9

AG-014699 (Rucaparib) is a PARP inhibitor that inhibits poly(ADP-ribose) polymerase (PARP) is a key enzyme in DNA repair.
The price depends on the options chosen on the product page

Starting at $25.00

View Sizes
AG14361

A10046 CAS 328543-09-5

AG14361 is a potent PARP inhibitor, enhanced TMZ cytotoxicity in MMR(mismatch repair)-proficient / deficient cells.
The price depends on the options chosen on the product page

Starting at $40.00

View Sizes
AZD-2461

A12393 CAS 1174043-16-3

AZD2461 is a novel and potent PARP inhibitor with lower affinity to P-glycoprotein.
The price depends on the options chosen on the product page

Starting at $25.00

View Sizes
PJ 34 hydrochloride

A12665 CAS 344458-15-7

PJ 34 hydrochloride is a potent inhibitor of poly(ADP-ribose) polymerase (PARP) (EC50 = 20 nM).
The price depends on the options chosen on the product page

Starting at $30.00

View Sizes
UPF 1069

A12750 CAS 1048371-03-4

UPF 1069 is a selective poly(ADP-ribose) polymerase (PARP) 2 inhibitor (IC50 values are 0.3 and 8.0 μM for PARP-2 and PARP-1 respectively).
The price depends on the options chosen on the product page

Starting at $25.00

View Sizes
Rucaparib

A14182 CAS 283173-50-2

Rucaparib is a potent inhibitor of purified full-length human PARP-1 and shows higher inhibition of cellular PARP in LoVo and SW620 cells.
The price depends on the options chosen on the product page

Starting at $35.00

View Sizes

Added to your cart

View Cart Checkout
Loading...